CLINICAL EXPERIENCE WITH CRIZOTINIB IN SPECIAL POPULATIONS WITH ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Ahn, M-J [1 ]
Crino, L. [2 ]
Solomon, Ben [3 ]
Zhou, Caicun [4 ]
Ou, Sai-hong I. [5 ]
Selaru, P. [6 ]
Cohen, D. P. [6 ]
Bartlett, C. H. [7 ]
Kim, Dong-wan [8 ]
机构：
[1] Samsung Med Ctr, Seoul, South Korea
[2] Osped S Maria Misericordia, Perugia, Italy
[3] Peter Maccallum Canc Ctr, Melbourne, Vic, Australia
[4] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Med Oncol, Shanghai, Peoples R China
[5] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Med Hematol Oncol, Orange, CA 92668 USA
[6] Pfizer Oncol, La Jolla, CA USA
[7] Pfizer Oncol, New York, NY USA
[8] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 11期
关键词：
poor performance status; brain metastases; elderly; crizotinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2-036
引用
收藏
页码：S490 / S491
页数：2
相关论文
共 50 条
  • [1] BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN COLOMBIA
    Rosado-Buzzo, A.
    Garcia-Mollinedo, L.
    Luna-Casas, G.
    Mould-Quevedo, J. F.
    Gutierrez-Ardila, M., V
    Vargas Zea, N.
    VALUE IN HEALTH, 2013, 16 (03) : A132 - A132
  • [2] Clinical observation of crizotinib in the treatment of ALK-positive advanced non-small cell lung cancer
    Deng, Huiyan
    Li, Bin
    Li, Lina
    Peng, Jingcui
    Lv, Tongshuai
    Liu, Yueping
    Ding, Cuimin
    PATHOLOGY RESEARCH AND PRACTICE, 2019, 215 (12)
  • [3] Clinical presentation of hepatotoxicity-associated crizotinib in ALK-positive (ALK plus ) advanced non-small cell lung cancer (NSCLC).
    Schnell, Patrick
    Safferman, Allan Zachary
    Bartlett, Cynthia Huang
    Tang, Yiyun
    Wilner, Keith D.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [4] ESTIMATING THE BUDGET IMPACT OF CRIZOTINIB FOR ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) IN ARGENTINA
    Wang, B.
    Furnback, W.
    Xuan, J.
    VALUE IN HEALTH, 2014, 17 (03) : A74 - A74
  • [5] Renal effects of crizotinib in patients (pts) with ALK-positive (+) advanced non-small cell lung cancer (NSCLC)
    Kim, E.
    Usari, T.
    Polli, A.
    Lewis, I.
    Wilner, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S134 - S134
  • [6] Crizotinib: A targeted therapy in advanced ALK-positive non-small cell lung cancer
    Toffart, A. -C.
    Sakhri, L.
    Moro-Sibilot, D.
    REVUE DE PNEUMOLOGIE CLINIQUE, 2013, 69 (02) : 111 - 116
  • [7] Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
    Kim, Dong-Wan
    Ahn, Myung-Ju
    Shi, Yuankai
    De Pas, Tommaso Martino
    Yang, Pan-Chyr
    Riely, Gregory J.
    Crino, Lucio
    Evans, Tracey L.
    Liu, Xiaoqing
    Han, Ji-Youn
    Salgia, Ravi
    Moro-Sibilot, Denis
    Ou, Sai-Hong Ignatius
    Gettinger, Scott N.
    Wu, Yi Long
    Lanzalone, Silvana
    Polli, Anna
    Iyer, Shrividya
    Shaw, Alice Tsang
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Results of A Global Phase II Study with Crizotinib in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Riely, G. J.
    Evans, T. L.
    Salgia, R.
    Ou, S. I.
    Gettinger, S. N.
    Otterson, G. A.
    Lanzalone, S.
    Polli, A.
    Shaw, A. T.
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S204 - S204
  • [9] CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066), IN ALK-POSITIVE PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC)
    Camidge, D. R.
    Bang, Y.
    Iafrate, A. J.
    Kwak, E. L.
    Maki, R. G.
    Solomon, B.
    Ou, S. I.
    Salgia, R.
    Shaw, A.
    Clark, J.
    ANNALS OF ONCOLOGY, 2010, 21 : 123 - 123
  • [10] Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005
    Crino, L.
    Kim, D.
    Riely, G. J.
    Janne, P. A.
    Blackhall, F. H.
    Camidge, D. R.
    Hirsh, V.
    Mok, T.
    Solomon, B. J.
    Park, K.
    Gadgeel, S. M.
    Martins, R.
    Han, J.
    De Pas, T. M.
    Bottomley, A.
    Polli, A.
    Petersen, J.
    Tassell, V. R.
    Shaw, A. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345